MedTrace Logo

Personalized Treatment for Refractory H Pylori Infection

NCT02547025 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 126

Last updated 2023-10-26

No results posted yet for this study

Summary

In this study, the investigators develop a personalized treatment according to culture-guided antibiotics plus high-dose proton-pump inhibitor and bismuth to treat refractory H pylori infection.

Conditions

  • Helicobacter Pylori Infection

Interventions

DRUG

rabeprazole+3 antibiotics

(rabeprazole 20 mg q.d.s. and three effective antibiotics) for 14 days.

DRUG

rabeprazole+bismuth+2 antibiotics

(rabeprazole 20 mg q.d.s., bismuth subcitrate 120 mg q.d.s. and all the effective antibiotics) for 14 days.

DRUG

rabeprazole+amox+tetr+levo

(rabeprazole 20 mg q.d.s, amoxicillin 500 mg q.d.s., tetracycline 500 mg q.d.s. and levofloxacin 500 mg o.d.) for 14 days.

Sponsors & Collaborators

  • Kaohsiung Medical University Chung-Ho Memorial Hospital

    collaborator OTHER

  • Kaohsiung Veterans General Hospital.

    lead OTHER

Principal Investigators

  • Ping-I Hsu, Bachelor · Kaohsiung Veterans General Hospital.

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-08-01
Primary Completion
2021-10-31
Completion
2021-10-31

Countries

  • Taiwan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02547025 on ClinicalTrials.gov